Difference between revisions of "Breast cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (moved Breast Cancer to Breast cancer: capitalization)
Line 1: Line 1:
 +
{{TOC limit|limit=3}}
 +
 
==Adjuvant Therapy==
 
==Adjuvant Therapy==
 +
 +
===TAC===
 +
TAC: '''<u>T</u>'''axotere, '''<u>A</u>'''driamycin, '''<u>C</u>'''ytoxan
 +
 +
====Regimen====
 +
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour on day 1 (administered third, one hour after cyclophosphamide)
 +
*[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV over 15 minutes on day 1 (administered first)
 +
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m2 IV over 1-5 minutes on day 1 (administered second)
 +
*[[Dexamethasone]] 8 mg PO every 12 hours x 6 total doses, starting the day before treatment
 +
*Ciprofloxacin 500 mg PO BID on days 5-14 of every cycle (prophylaxis)
 +
*G-CSF not originally routinely administered unless patients had febrile neutropenia, but NCCN recommends routine filgratim support:
 +
:*[[Filgrastim (Neupogen)]] 5 mcg/kg SC on days 4-11
 +
:*Lenograstim 150 mcg/m2 on days 4-11
 +
 +
'''21-day cycles x 6 cycles'''
 +
 +
====References====
 +
# Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. [http://www.nejm.org/doi/full/10.1056/NEJMoa043681 link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/15930421 PubMed]
 +
 +
===FAC #1===
 +
FAC: '''<u>F</u>'''ive-FU, '''<u>A</u>'''driamycin, '''<u>C</u>'''ytoxan <br>
 +
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV over 15 minutes on day 1 (administered second)
 +
*[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV over 15 minutes on day 1 (administered first)
 +
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m2 IV over 1-5 minutes on day 1 (administered third)
 +
*If patients had febrile neutropenia or infection: Ciprofloxacin 500 mg PO BID on days 5-14 of every cycle (prophylaxis)
 +
*G-CSF not originally routinely administered unless patients had febrile neutropenia:
 +
:*[[Filgrastim (Neupogen)]] 5 mcg/kg SC on days 4-11
 +
:*Lenograstim 150 mcg/m2 on days 4-11
 +
 +
'''21-day cycles x 6 cycles'''
 +
 +
====References====
 +
# Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. [http://www.nejm.org/doi/full/10.1056/NEJMoa043681 link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/15930421 PubMed]
 +
 
==Metastatic Disease==
 
==Metastatic Disease==
−
===Single agents===
+
===Eribulin (Halaven)===
−
====Eribulin (Halaven)====
+
====Regimen====
 
*[[Eribulin (Halaven)]] 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8
 
*[[Eribulin (Halaven)]] 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8
  
 
'''21-day cycles'''
 
'''21-day cycles'''
  
−
=====References=====
+
====References====
 
# Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.  Lancet. 2011 Mar 12;377(9769):914-23. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed]
 
# Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.  Lancet. 2011 Mar 12;377(9769):914-23. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed]
  
−
====Ixabepilone (Ixempra)====
+
===Ixabepilone (Ixempra)===
 +
====Regimen====
 
*[[Ixabepilone (Ixempra)]] 40 mg/m2 IV on day 1
 
*[[Ixabepilone (Ixempra)]] 40 mg/m2 IV on day 1
 
*[[Capecitabine (Xeloda)]] 2,000 mg/m2 orally on days 1 through 14
 
*[[Capecitabine (Xeloda)]] 2,000 mg/m2 orally on days 1 through 14
Line 16: Line 55:
 
'''21-day cycles'''
 
'''21-day cycles'''
  
−
=====References=====
+
====References====
−
#Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.  J Clin Oncol. 2010 Jul 10;28(20):3256-63.[http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20530276/?tool=pubmed link to original article]'''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/20530276 PubMed]
+
# Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.  J Clin Oncol. 2010 Jul 10;28(20):3256-63.[http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20530276/?tool=pubmed link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/20530276 PubMed]
−
#Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [http://www.jco.org/cgi/pmidlookup?view=long&pmid=17968020]'''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/17968020 PubMed]
+
# Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [http://www.jco.org/cgi/pmidlookup?view=long&pmid=17968020] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/17968020 PubMed]

Revision as of 04:06, 19 February 2012


Adjuvant Therapy

TAC

TAC: Taxotere, Adriamycin, Cytoxan

Regimen

  • Docetaxel (Taxotere) 75 mg/m2 IV over 1 hour on day 1 (administered third, one hour after cyclophosphamide)
  • Doxorubicin (Adriamycin) 50 mg/m2 IV over 15 minutes on day 1 (administered first)
  • Cyclophosphamide (Cytoxan) 500 mg/m2 IV over 1-5 minutes on day 1 (administered second)
  • Dexamethasone 8 mg PO every 12 hours x 6 total doses, starting the day before treatment
  • Ciprofloxacin 500 mg PO BID on days 5-14 of every cycle (prophylaxis)
  • G-CSF not originally routinely administered unless patients had febrile neutropenia, but NCCN recommends routine filgratim support:

21-day cycles x 6 cycles

References

  1. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. link to original article (contains protocol) PubMed

FAC #1

FAC: Five-FU, Adriamycin, Cytoxan

Regimen

  • Fluorouracil (5-FU) 500 mg/m2 IV over 15 minutes on day 1 (administered second)
  • Doxorubicin (Adriamycin) 50 mg/m2 IV over 15 minutes on day 1 (administered first)
  • Cyclophosphamide (Cytoxan) 500 mg/m2 IV over 1-5 minutes on day 1 (administered third)
  • If patients had febrile neutropenia or infection: Ciprofloxacin 500 mg PO BID on days 5-14 of every cycle (prophylaxis)
  • G-CSF not originally routinely administered unless patients had febrile neutropenia:

21-day cycles x 6 cycles

References

  1. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. link to original article (contains protocol) PubMed

Metastatic Disease

Eribulin (Halaven)

Regimen

21-day cycles

References

  1. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. link to original article (contains protocol) PubMed

Ixabepilone (Ixempra)

Regimen

21-day cycles

References

  1. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63.link to original article (contains protocol) PubMed
  2. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [1] (contains protocol) PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer&oldid=828"